Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Biotinylated Human ITGAV&ITGB3 Heterodimer Protein, His, Avitag™&Tag Free, produced by co-expression of ITGAV and ITGB3, has a calculated MW of 114.6 kDa (ITGAV) and 81.8 kDa (ITGB3). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and an Avi tag (Avitag™) and subunit ITGB3 contains no tag but a basic tail at the C-terminus. The predicted N-terminus is Phe 31 (ITGAV) & Gly 27 (ITGB3). The non-reducing (NR) protein migrates as 135 kDa (ITGAV) & 80 kDa (ITGB3) respectively due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human ITGAV&ITGB3 Heterodimer Protein, His,Avitag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Biotinylated Human ITGAV&ITGB3 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT3-H82W9) is more than 85% and the molecular weight of this protein is around 200-245 kDa verified by SEC-MALS.
Immobilized Human Vitronectin Protein, premium grade (Cat. No. VIN-H5214) at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB3 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT3-H82W9) with a linear range of 0.01-1.25 μg/mL (QC tested).
Price(USD) : $360.00
Price(USD) : $1420.00
Price(USD) : $35.00
Price(USD) : $140.00
Price(USD) : $50.00
Price(USD) : $125.00
Price(USD) : $140.00
Price(USD) : $235.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Alfatide[18F] | 18F-AlF-NOTA-PRGD2; 18F-alfatide; alfatide II; AlF-NOTA-PRGD2-[18F] | Phase 3 Clinical | Jiangsu Smk Pharmaceutical Co Ltd, Taizhou Kairui Pharmaceutical Technology Co Ltd | Head and Neck Neoplasms; Carcinoma, Bronchogenic; Neoplasms; Soft Tissue Neoplasms; Breast Neoplasms; Contrast agents; Lymphoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
18F-LNC1016 | 18F-LNC1016; 18F-LNC-1016 | Phase 3 Clinical | Shanghai Lannacheng Biotechnology Co Ltd | Lung Neoplasms | Details |
IDL-2965 | IDL-2965 | Phase 2 Clinical | Indalo Therapeutics Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Idiopathic Pulmonary Fibrosis | Details |
AS-101 | PRX-0001/AS101; WAX-120337; IVAX-Q-101; IVX-Q-101; CB-06-02; AS-101; PRX-001; PRX-0002/AS101 | Phase 2 Clinical | Biomas Ltd | HIV Infections; Alopecia; Warts; Myelodysplastic Syndromes; Psoriasis; Leukemia, Myeloid, Acute; Thrombocytopenia; Condylomata Acuminata; Dermatitis, Atopic; Macular Degeneration | Details |
Nesvategrast | OTT-166(OcuTerra Therapeutics); SF-0166 | Phase 2 Clinical | Scifluor Life Sciences Inc, OcuTerra Therapeutics Inc | Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration | Details |
ProAgio | Phase 2 Clinical | National Cancer Institute | Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms | Details | |
Ga-68 NODAGA-RGD | [68Ga]Theranost; Theranost 68Ga-RGD | Phase 1 Clinical | Advanced Imaging Projects, Zentralklinik Bad Berka, National Cancer Institute | Neovascularization, Pathologic; Lung Neoplasms | Details |
Risuteganib | ALG-1001; AM011; AM-011(Allegro Ophthalmics) | Phase 1 Clinical | Allegro Ophthalmics Llc | Diabetic macular oedema; Geographic Atrophy; Diabetic Retinopathy; Macular Degeneration | Details |
68Ga-NOTA-BBN-RGD | 68Ga-NOTA-BBN-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms; Prostatic Neoplasms | Details |
BGC-0222 | BGC0222; BGC-0222 | Phase 1 Clinical | Gaorui Yaoye (Beijing) Technologies Co Ltd, Brightgene Bio-Medical Technology Co Ltd | Solid tumours | Details |
Antiangiotide | HM-3; IIM-3 | Phase 1 Clinical | Inner Mongolia Tianqi Pharmaceutical Group Co Ltd, China Pharmaceutical University | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
68Ga-NOTA-3PTATE-RGD | 68Ga-NOTA-3PTATE-RGD; 68Ga-NOTA-3P-TATE-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Neuroendocrine Tumors; Lung Neoplasms; Meningioma | Details |
FF-10158 | FF-10158 | Phase 1 Clinical | Fujifilm Holdings Corp | Glioblastoma | Details |
Transferrin | OCU-200 | Phase 1 Clinical | Ocugen Inc | Wet Macular Degeneration; Diabetic macular oedema; Diabetic Retinopathy | Details |
VIP-236 | VIP-236 | Phase 1 Clinical | Bayer AG | Solid tumours; Neoplasms | Details |
177Lu-FAPI-RGD | 177Lu-FAPI-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Neoplasms | Details |
177Lu-LNC1008 | 177Lu-LNC1008 | Phase 1 Clinical | Shanghai Lannacheng Biotechnology Co Ltd | Solid tumours | Details |
68Ga-FAPI-RGD | 68Ga-FAPI-RGD; 68Ga-LNC-1007 | Phase 1 Clinical | Peking Union Medical College Hospital, Fujian Medical University | Carcinoma, Renal Cell; Neoplasms; Lung Neoplasms | Details |
NP-011 | NP-011 | Phase 1 Clinical | Nexell Therapeutics Inc | Myocardial Infarction | Details |
68Ga-HX01 | 68GaHX01; 68Ga-HX01 | Phase 1 Clinical | Hexin (Suzhou) Pharmaceutical Technology Co Ltd | Solid tumours; Neoplasms; Contrast agents | Details |
(68)Ga-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Keloid | Details | |
fb-PMT | NP-100; NP-751 | Phase 1 Clinical | NanoPharmaceuticals LLC | Glioma | Details |
ACT-50 | ACT-50 | Phase 1 Clinical | Xiamen Amoytop Biotech Co Ltd | Neoplasms; Carcinoma, Pancreatic Ductal | Details |
Pagantangentide | Phase 1 Clinical | Nanjing Anji Biological Technology Co Ltd, Jiangsu Aotexin Biomedical Technology Co Ltd, China Pharmaceutical University | Arthritis, Rheumatoid; Rheumatic Diseases | Details |
This web search service is supported by Google Inc.